ArticleBMC women's health2026
Phenotype-specific efficacy of letrozole versus clomiphene citrate in polycystic ovary syndrome: a prospective cohort study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the efficacy of letrozole (LT) versus clomiphene citrate (CC) for ovulation induction (OI) in women with polycystic ovary syndrome (PCOS), with emphasis on phenotypic variation and hyperandrogenism severity.
methodsIn this prospective cohort study, 207 infertile women with PCOS diagnosed by modified Rotterdam criteria were treated with escalating doses of LT (n = 103) or CC (n = 104). Patients were classified according to PCOS phenotype (A–D) and hyperandrogenism markers: modified Ferriman-Gallwey (mFG) score, total testosterone (tT), and free androgen index (FAI). The primary outcome was ovulation; secondary outcomes included clinical pregnancy and live birth rates.
resultsLT achieved significantly higher ovulation rates compared with CC (93.2% vs. 77.9%, P = 0.002). The superiority of LT was most evident in patients with mFG > 8 (94.4% vs. 78.9%, P = 0.005), FAI ≥ 7 (100% vs. 50%, P = 0.006), and tT ≥ 48 ng/dL, where LT also resulted in higher clinical pregnancy and live birth rates. Phenotype C patients showed the clearest benefit with LT (100% vs. 82.6%, P = 0.013), while no significant differences were observed in non-hyperandrogenic (Phenotype D) patients. Multivariate analysis identified age and FAI as independent predictors of clinical pregnancy. In multivariate analysis adjusted for age, BMI, and hirsutism scores, Letrozole remained a significant independent predictor of ovulation (aOR: 7.74, p = 0.008).
conclusionIn this prospective observational study, Letrozole was associated with higher ovulation and pregnancy rates compared to clomiphene citrate in hyperandrogenic PCOS patients, particularly those with elevated FAI, tT, or hirsutism. Both agents demonstrated comparable efficacy in non-hyperandrogenic (Phenotype D) patients. These associative findings suggest that androgen markers may help guide individualized treatment selection, though further randomized controlled trials are needed to confirm these exploratory subgroup observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.